Abstract
Iron oxide (IO) nanoparticles hold great promise as diagnostic and therapeutic agents in oncology. Their intrinsic physical properties make IO nanoparticles particularly interesting for simultaneous drug delivery, molecular imaging, and applications such as localized hyperthermia. Multiple non-targeted IO nanoparticle preparations have entered clinical trials, but more exciting, new tumortargeted IO nanoparticle preparations are currently being tested in preclinical settings. This paper will analyze the challenges faced by this new theranostic modality, with a specific focus on the interactions of IO nanoparticles with the innate and adaptive immune systems, and their effect on nanoparticle biodistribution and tumor targeting. Next, we will review the critical need for innovative surface chemistry solutions and strategies to overcome the immune interactions that prevent existing tumor-targeted IO preparations from entering clinical trials. Finally, we will provide an outlook for the future role of IO nanoparticles in oncology, which have the promise of becoming significant contributors to improved diagnosis and treatment of cancer patients.
Keywords: Iron oxide nanoparticles, tumor targeting, immunology, inflammation, macrophage, nanoparticle surface chemistry, cancer theranostics.
Current Pharmaceutical Design
Title:Interactions of Iron Oxide Nanoparticles with the Immune System: Challenges and Opportunities for their Use in Nano-oncology
Volume: 19 Issue: 37
Author(s): Dana C. Baiu, Christopher S. Brazel, Yuping Bao and Mario Otto
Affiliation:
Keywords: Iron oxide nanoparticles, tumor targeting, immunology, inflammation, macrophage, nanoparticle surface chemistry, cancer theranostics.
Abstract: Iron oxide (IO) nanoparticles hold great promise as diagnostic and therapeutic agents in oncology. Their intrinsic physical properties make IO nanoparticles particularly interesting for simultaneous drug delivery, molecular imaging, and applications such as localized hyperthermia. Multiple non-targeted IO nanoparticle preparations have entered clinical trials, but more exciting, new tumortargeted IO nanoparticle preparations are currently being tested in preclinical settings. This paper will analyze the challenges faced by this new theranostic modality, with a specific focus on the interactions of IO nanoparticles with the innate and adaptive immune systems, and their effect on nanoparticle biodistribution and tumor targeting. Next, we will review the critical need for innovative surface chemistry solutions and strategies to overcome the immune interactions that prevent existing tumor-targeted IO preparations from entering clinical trials. Finally, we will provide an outlook for the future role of IO nanoparticles in oncology, which have the promise of becoming significant contributors to improved diagnosis and treatment of cancer patients.
Export Options
About this article
Cite this article as:
C. Baiu Dana, S. Brazel Christopher, Bao Yuping and Otto Mario, Interactions of Iron Oxide Nanoparticles with the Immune System: Challenges and Opportunities for their Use in Nano-oncology, Current Pharmaceutical Design 2013; 19 (37) . https://dx.doi.org/10.2174/13816128113199990409
DOI https://dx.doi.org/10.2174/13816128113199990409 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Aging and Remodeling During Healing of the Wounded Heart: Current Therapies and Novel Drug Targets
Current Drug Targets The Urokinase Plasminogen Activator System: Role in Malignancy
Current Pharmaceutical Design Editorial
Current Medical Imaging Homocysteine and Non-Cardiac Vascular Disease
Current Pharmaceutical Design Intracranial Non-traumatic Aneurysms in Children and Adolescents
Current Pediatric Reviews Natural Products to Anti-trypanosomal Drugs: An Overview of New Drug Prototypes for American Trypanosomiasis
Cardiovascular & Hematological Agents in Medicinal Chemistry The Yin and Yang of BK Channels in Epilepsy
CNS & Neurological Disorders - Drug Targets Fluorescein Fluorescence Use in the Management of Intracranial Neoplastic and Vascular Lesions: A Review and Report of a New Technique
Current Drug Discovery Technologies Update on Sirolimus Drug-Eluting Stents
Current Pharmaceutical Design Meet Our Editor:
Current Cardiology Reviews New Insights into the Biology of 1-Antitrypsin and its Role in Chronic Obstructive Pulmonary Disease
Current Respiratory Medicine Reviews Endothelial Dysfunction and Coronary Atherosclerosis
Current Drug Targets - Cardiovascular & Hematological Disorders FDG-PET in the Evaluation of Brain Metabolic Changes Induced by Cognitive Stimulation in aMCI Subjects
Current Radiopharmaceuticals Dyslipidaemia Related to Insulin Resistance and Cardiovascular Disease in South Asian and West African Populations
Current Pharmaceutical Design Contributory Role of Matrix Metalloproteinases in Cardiovascular Remodeling
Current Drug Targets - Cardiovascular & Hematological Disorders Lipoprotein (a) and Cardiovascular Risk: The Show Must go on
Current Medicinal Chemistry Cell Immunity in Inflammatory Vasculitis
Current Immunology Reviews (Discontinued) Matrix Metalloproteinases
Current Medicinal Chemistry Proteomic Analysis of Liver Preservation Solutions Prior to Liver Transplantation
Current Proteomics A Cerebrovascular Image Segmentation Method Based on Geometrical Feature Point Clustering and Local Threshold
Current Medical Imaging